Development of immunohistochemistry assays to assess GALNT14 and FUT3/6 in clinical trials of dulanermin and drozitumab.

Source:http://linkedlifedata.com/resource/pubmed/id/20179215

Clin. Cancer Res. 2010 Mar 1 16 5 1587-96

Download in:

View as

General Info

PMID
20179215